Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL4297809

ELRANATAMAB
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
No structure available
ChEMBL ↗

Basic Information

ChEMBL ID CHEMBL4297809
Name ELRANATAMAB
Phase Approved
Structure Type SEQ
Therapeutic ✓ Yes

Known Names

Elranatamab Elranatamab-bcmm Elrexfio Pf-06863135 RN-613 RN613
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
6
Known Names
3
Indications
2
Mechanisms

Drug Information

Molecule Type Antibody
First Approval 2023
Availability Prescription
Chirality Single Enantiomer

Routes of Administration

Parenteral

Flags

Black Box Warning
USAN Stem -mab
USAN Year 2021

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
T cell surface glycoprotein CD3 binding agent BINDING AGENT T cell surface glycoprotein CD3 ✓ ✓
Tumor necrosis factor receptor superfamily member 17 binding agent BINDING AGENT Tumor necrosis factor receptor superfamily member 17 ✓ ✓

Indications

Multiple Myeloma Neoplasms Smoldering Multiple Myeloma

ATC Classification

L01FX32
elranatamab
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: ANTINEOPLASTIC AGENTS

Drug Warnings

Black Box Warning
General Warning
Country: United States

Data from ChEMBL 36 via Core Engine